Clicky

H Lundbeck A/S B Shares [Denmark](HLBBF)

Description: H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.


Keywords: Biopharmaceutical Drugs Psychoactive Drugs Alzheimer's Disease Parkinson's Disease Schizophrenia Depression Epilepsy Mood Stabilizers Migraine Huntington's Disease Antidepressants Psychiatric And Neurological Disorders Chorea Migraine Prevention Aripiprazole Lundbeck Treatment Of Psychiatric And Neurological Disorders Abilify Maintena Azilect Brintellix Depression/Schizophrenia Ebixa Escitalopram Migraine Therapy Northera Onfi Rasagiline Sabril Symptomatic Neurogenic Orthostatic Hypotension Valby Xenazine

Home Page: www.lundbeck.com

Ottiliavej 9
Valby, 2500
Denmark
Phone: 45 36 30 13 11


Officers

Name Title
Mr. Charl van Zyl President & CEO
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions
Mr. Lars Bang Executive Vice President of Product Development & Supply
Dr. Per Johan Luthman Ph.D. Executive Vice President of Research & Development
Dr. Tarek Samad Ph.D. Senior VP & Head of Research
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs
Ms. Dianne Holto Executive Vice President of People & Culture
Mr. Ole Chrintz Senior Vice President of International Markets
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 13.4953
Trailing PE: 16.0526
Price-to-Book MRQ: 1.802
Price-to-Sales TTM: 2.0026
IPO Date:
Fiscal Year End: December
Full Time Employees: 5681
Back to stocks